Figure 6 shows further investigation into the specific immune cell types, which revealed that in addition to enriched CD8+ T cells, KRAS-mutant NSCLC showed a similar intratumoral immune profile to triple wild-type NSCLC patients. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.